FDA clears first outpatient BPDCN antibody-drug conjugate for rare blood cancer - Stock Titan
Stock Titan reports on FDA clears first outpatient BPDCN antibody-drug conjugate for rare blood cancer in Science & Health.
Take A Coffee NEWS Staff··2 min read
Stock Titan reported FDA clears first outpatient BPDCN antibody-drug conjugate for rare blood cancer. Take A Coffee NEWS is tracking the story on the Science & Health desk for readers following medicine, public health, research, climate, space, and science policy.
Source
Why it matters
The story belongs in this desk because it may affect readers tracking medicine, public health, research, climate, space, and science policy.